-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $75

Benzinga·08/05/2026 13:59:09
Listen to the news
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $65 to $75.